Literature DB >> 15976503

Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility study.

Sean I Savitz1, Jonathan Dinsmore, Julian Wu, Galen V Henderson, Philip Stieg, Louis R Caplan.   

Abstract

BACKGROUND: Cell transplantation is safe in animal models and enhances recovery from stroke in rats.
METHODS: We studied the safety and feasibility of fetal porcine transplantation in 5 patients with basal ganglia infarcts and stable neurological deficits. To prevent rejection, cells were pretreated with an anti-MHC1 antibody and no immunosuppressive drugs were given to the patients.
RESULTS: The first 3 patients had no adverse cell, procedure, or imaging-defined effects. The fourth patient had temporary worsening of motor deficits 3 weeks after transplantation, and the fifth patient developed seizures 1 week after transplantation. MRI in both patients demonstrated areas of enhancement remote from the transplant site, which resolved on subsequent imaging. Two patients showed improvement in speech, language, and/or motor impairments over several months and persisted at 4 years. The study was terminated by the FDA after the inclusion of 5 patients.
CONCLUSION: This is the first report on the transplantation of nontumor cells in ischemic stroke patients. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15976503     DOI: 10.1159/000086518

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  74 in total

Review 1.  Intra-arterial delivery of cell therapies for stroke.

Authors:  Vivek Misra; Aditya Lal; Ramy El Khoury; Peng R Chen; Sean I Savitz
Journal:  Stem Cells Dev       Date:  2012-02-15       Impact factor: 3.272

2.  Large animal models are critical for rationally advancing regenerative therapies.

Authors:  Dustin R Wakeman; Andrew M Crain; Evan Y Snyder
Journal:  Regen Med       Date:  2006-07       Impact factor: 3.806

Review 3.  Cell-based therapy in ischemic stroke.

Authors:  David C Hess; Cesar V Borlongan
Journal:  Expert Rev Neurother       Date:  2008-08       Impact factor: 4.618

4.  Intracranial delivery of stem cells.

Authors:  Keith W Muir; John Sinden; Erik Miljan; Laurence Dunn
Journal:  Transl Stroke Res       Date:  2011-07-26       Impact factor: 6.829

Review 5.  Current status of cell therapies in stroke.

Authors:  Oh Young Bang
Journal:  Int J Stem Cells       Date:  2009-05       Impact factor: 2.500

Review 6.  Developing Cellular Therapies for Stroke.

Authors:  Sean I Savitz
Journal:  Stroke       Date:  2015-06-04       Impact factor: 7.914

7.  Cell therapy for ischaemic stroke.

Authors:  D C Hess; W D Hill
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

Review 8.  Opportunities and challenges: stem cell-based therapy for the treatment of ischemic stroke.

Authors:  Yao-Hui Tang; Yuan-Yuan Ma; Zhi-Jun Zhang; Yong-Ting Wang; Guo-Yuan Yang
Journal:  CNS Neurosci Ther       Date:  2015-02-10       Impact factor: 5.243

Review 9.  Cell Therapy for Ischemic Stroke: How to Turn a Promising Preclinical Research into a Successful Clinical Story.

Authors:  Gabrielle Mangin; Nathalie Kubis
Journal:  Stem Cell Rev Rep       Date:  2019-04       Impact factor: 5.739

10.  Stem cell transplantation for ischemic stroke.

Authors:  Giorgio Battista Boncoraglio; Michela Ranieri; Anna Bersano; Eugenio A Parati; Cinzia Del Giovane
Journal:  Cochrane Database Syst Rev       Date:  2019-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.